Drug profile

The FDA adverse-event record for Iv Fluids

117 FDA reports name Iv Fluids, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#720 of 2,679
by report volume (all drugs)
117
adverse-event reports
47.0%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Iv Fluids ranks #717 of 2679 by total reports (117) and #68 of 1130 by death-coded share (47.0%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#717
This drug, reports of 2679
#68
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Iv Fluids has 117 reports now versus 117 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Iv Fluids changes

Signature read: Iv Fluids's 47.0% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
117
Total Reports
55
Deaths Reported
47.0%
Death-coded share of reports

Active Ingredients

Iv Fluids

Administration Routes

IntravenousUnknownParenteralIntramuscular

Species Affected

Dog 83
Cat 33
Alpaca 1

Most Affected Breeds

Domestic Shorthair 25
Retriever - Labrador 12
Shih Tzu 7
Crossbred Canine/dog 5
Terrier - Yorkshire 4
Retriever - Golden 4
Dog (unknown) 3
Bulldog - French 3
Shepherd Dog - German 3
Chihuahua 3

Most Reported Reactions

Death 27
Vomiting 27
Death by euthanasia 27
Lethargy (see also Central nervous system depression in 'Neurological') 23
Elevated blood urea nitrogen (BUN) 19
Dehydration 17
Not eating 16
Elevated creatinine 15
Anorexia 14
Diarrhoea 13
Abnormal radiograph finding 13
Anaemia NOS 11

Outcome Breakdown

Died
28 (23.7%)
Euthanized
27 (22.9%)
Ongoing
24 (20.3%)
Recovered/Normal
23 (19.5%)
Outcome Unknown
16 (13.6%)

Iv Fluids: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Iv Fluids, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Iv Fluids (#720 of 2,679 by report volume); death-coded 47.0%. PlainBreed drug row · death-coded share stamp 47.0% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →